WO2024005726A1 - Storage stable topical composition comprising clobetasol - Google Patents
Storage stable topical composition comprising clobetasol Download PDFInfo
- Publication number
- WO2024005726A1 WO2024005726A1 PCT/TR2022/050686 TR2022050686W WO2024005726A1 WO 2024005726 A1 WO2024005726 A1 WO 2024005726A1 TR 2022050686 W TR2022050686 W TR 2022050686W WO 2024005726 A1 WO2024005726 A1 WO 2024005726A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- topical
- clobetasol
- pharmaceutical composition
- formulation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 71
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 title claims abstract description 42
- 229960002842 clobetasol Drugs 0.000 title claims abstract description 12
- 238000003860 storage Methods 0.000 title claims abstract description 12
- 230000000699 topical effect Effects 0.000 title description 22
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 27
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000012049 topical pharmaceutical composition Substances 0.000 claims abstract description 18
- 229940082500 cetostearyl alcohol Drugs 0.000 claims abstract description 9
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229940075529 glyceryl stearate Drugs 0.000 claims abstract description 8
- 239000003002 pH adjusting agent Substances 0.000 claims abstract description 6
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims abstract 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 42
- 239000006071 cream Substances 0.000 claims description 24
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000003755 preservative agent Substances 0.000 claims description 7
- 229960002242 chlorocresol Drugs 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 6
- 230000000845 anti-microbial effect Effects 0.000 claims description 5
- 235000013871 bee wax Nutrition 0.000 claims description 5
- 239000012166 beeswax Substances 0.000 claims description 5
- 230000002335 preservative effect Effects 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- 239000001509 sodium citrate Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 abstract description 23
- 239000000047 product Substances 0.000 description 37
- 229960004703 clobetasol propionate Drugs 0.000 description 26
- 239000008186 active pharmaceutical agent Substances 0.000 description 20
- 239000000546 pharmaceutical excipient Substances 0.000 description 20
- 210000003491 skin Anatomy 0.000 description 20
- 239000012071 phase Substances 0.000 description 17
- 239000003995 emulsifying agent Substances 0.000 description 14
- 201000004681 Psoriasis Diseases 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 239000003246 corticosteroid Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- 201000004624 Dermatitis Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 238000005191 phase separation Methods 0.000 description 8
- 229960001334 corticosteroids Drugs 0.000 description 7
- 238000007925 in vitro drug release testing Methods 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 239000013543 active substance Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229960004106 citric acid Drugs 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229940075507 glyceryl monostearate Drugs 0.000 description 4
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229940100460 peg-100 stearate Drugs 0.000 description 3
- 230000000149 penetrating effect Effects 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 229960000999 sodium citrate dihydrate Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 229940100611 topical cream Drugs 0.000 description 3
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 3
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000002144 chemical decomposition reaction Methods 0.000 description 2
- 229960002303 citric acid monohydrate Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229960002479 isosorbide Drugs 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 201000011486 lichen planus Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001823 pruritic effect Effects 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 239000008299 semisolid dosage form Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000006208 topical dosage form Substances 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000037365 barrier function of the epidermis Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- ALSTYHKOOCGGFT-UHFFFAOYSA-N cis-oleyl alcohol Natural products CCCCCCCCC=CCCCCCCCCO ALSTYHKOOCGGFT-UHFFFAOYSA-N 0.000 description 1
- FCSHDIVRCWTZOX-DVTGEIKXSA-N clobetasol Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O FCSHDIVRCWTZOX-DVTGEIKXSA-N 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- LLRANSBEYQZKFY-UHFFFAOYSA-N dodecanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCCCCCC(O)=O LLRANSBEYQZKFY-UHFFFAOYSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 210000001513 elbow Anatomy 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000012395 formulation development Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000005337 ground glass Substances 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000012009 microbiological test Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 150000003145 progesterone derivatives Chemical class 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 229940125379 topical corticosteroid Drugs 0.000 description 1
- 229940025703 topical product Drugs 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000007332 vesicle formation Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Definitions
- a new topical formulation with high stability is provided, the composition comprising clobetasol or pharmaceutically acceptable salts thereof. It is associated with disorders including psoriasis, eczema, and other forms of dermatitis with exhibiting physical and chemical stability at long term shelf life stability condition.
- Clobetasol propionate is a synthetic, fluorinated corticosteroid with chemical name 21- chloro-9-fluoro-1 ip-hydroxy-16p-methyl-3,20- dioxopregna-1 ,4-dien- 17-yl propanoate, and it has the following structural formula (Formula I) with having only one polymorphic form and chiral with 8 stereogenic centers:
- Clobetasol propionate has an empirical formula of C25H32CIFO5 and a molecular weight of 467 g/mol. It is a white to cream-colored crystalline powder practically insoluble in water. It has been shown to be physically and chemically stable at room temperature (25°C/60% RH). Clobetasol is a very potent topical corticosteroid indicated for adults, elderly and children over 1 year for the short term treatment only of more resistant inflammatory and pruritic manifestations of steroid responsive dermatoses unresponsive to less potent corticosteroids.
- psoriasis excluding widespread plaque psoriasis
- recalcitrant dermatoses excluding widespread plaque psoriasis
- lichen planus excluding widespread plaque psoriasis
- recalcitrant dermatoses excluding widespread plaque psoriasis
- lichen planus excluding widespread plaque psoriasis
- recalcitrant dermatoses excluding widespread plaque psoriasis
- lichen planus excluding discoid lupus erythematosus and other skin conditions which do not respond satisfactorily to less potent steroids.
- Topical clobetasol propionate is a corticosteroid that is currently one of the most used treatments for psoriasis and its safety and efficacy is well defined in the medical literature.
- the cream dosage form of clobetasol propionate is commercially marketed under the trade name of Dermovate® (GlaxoSmithKline, UK) comprising clobetasol propionate 0.05% (w/w).
- Dermatitis is a superficial inflammation of the skin, characterized by vesicle formation, erythema, edema, oozing, scaling or crusting lesions, and intense itching.
- Different types of dermatitis can be distinguished: contact dermatitis, caused by irritants in contact with the skin or by non-irritating substances, to which the subject is allergic; atopic dermatitis, characterized by strong itching and a chronic course; and seborrheic dermatitis, a scaling disease mainly affecting the face and scalp.
- dermatitis a chronic, inflammatory, hyper proliferative recurring disease, which affects the skin and joints. In its most typical form, it causes thick, red, scaly patches, called psoriatic plaques, to appear on the skin. Skin rapidly accumulates at these sites and takes on a silvery-white appearance. Plaques most often occur on the skin of the elbows, knees, scalp, lower back, face, palms, and soles of the feet but can affect any skin site.
- dermatitis or inflammation of the epidermis is eczema, persistent skin conditions including dryness and recurring skin rashes.
- Other skin and mucous membrane conditions include disorders in the mouth, in the vagina, anus, ear and the eyes.
- Lichen planus is a chronic mucocutaneous disease that affects the skin and the oral mucosa, and presents itself in the form of papules, lesions or rashes.
- Psoriasis is a lifelong disorder with onset at any time throughout life, affecting men and women equally and afflicts almost all races in varying frequency rates. Psoriasis usually appears first between the ages of 15 and 30 years and may occur anywhere on the body. Psoriasis causes significant psychological and social distress, and significantly impacts quality of life. Unsatisfactory treatment of the disorder has a considerable adverse impact on patient’s quality of life with patients complaining about the messiness of the topical agents used.
- Clobetasol propionate is commercially available in compositions for topical application in form of lotion, spray, cream or shampoo. Moreover, various topical pharmaceutical compositions comprising clobetasol propionate has been proposed in the prior art, claiming the use of particular carriers or excipients.
- WO 2006115987 in the name of Dow Pharmaceutical Sciences provides a method for treating psoriasis by spraying a pharmaceutical composition containing an effective amount of clobetasol propionate onto the skin with psoriasis, using a daily treatment for at least 4 weeks.
- the preferred composition is a spray formulation of clobetasol propionate 0.05%, containing alcohol, isopropyl myristate, an anionic surfactant such as sodium lauryl sulfate, and optionally an antimicrobial compound such as an antifungal compound like undecylenic acid.
- WO 2007104895 and WO 2007104897 in the name of Galderma disclosed oil-in-water (o/w) anti-inflammatory emulsions, containing: a) a therapeutically effective amount of at least one steroidal anti-inflammatory agent, notably clobetasol propionate; b) a propenetrating system which includes at least one pro-penetrating glycol and at least one other pro-penetrating agent; a polymeric or non-polymeric emulsifier or one gelling agent.
- steroidal anti-inflammatory agent notably clobetasol propionate
- a propenetrating system which includes at least one pro-penetrating glycol and at least one other pro-penetrating agent
- a polymeric or non-polymeric emulsifier or one gelling agent a polymeric or non-polymeric emulsifier or one gelling agent.
- preferred pro-penetration system are: propylene glycol and isosorbide dimethyl, propylene glycol and ethanol; propylene glycol, monoethylether of diethylene glycol and propylene glycol laurate; propylene glycol and methyl pyrrolidone; propylene glycol, isosorbide dimethyl and ethanol; propylene glycol, methyl pyrrolidone and oleic alcohol.
- clobetasol in combination with at least a further active ingredient, such as calcitriol (Vitamin D) (see for example W02008110815, EP 1854.466, EP 1875916, US Patent No.2005281850, US Patent No. 2006009426 and FR 2848454): a progesterone derivative (EP 1473300); a prostaglandin (W003092617); or tazarotene (CA2282682).
- calcitriol Vitamin D
- a progesterone derivative EP 1473300
- a prostaglandin W003092617)
- tazarotene CA2282682
- Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation.
- Topical corticosteroids can be absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the product formulation and the integrity of the epidermal barrier. Occlusion, inflammation, and/or other disease processes in the skin may also increase percutaneous absorption.
- topical corticosteroids Once absorbed through the skin, topical corticosteroids are metabolized, primarily in the liver, and are then excreted by the kidneys. Some corticosteroids and their metabolites are also excreted in the bile.
- Dermatological corticosteroids and in particular clobetasol propionate have been provided in a variety of topical formulations such as creams, lotions, gels and the like in attempts to increase the delivery efficiency.
- topical formulations such as creams, lotions, gels and the like in attempts to increase the delivery efficiency.
- these formulations have not provided a complete solution to the problems connected with the stability problems due to degradation of topical compositions.
- clobetasol propionate was found to be incompatible with alkaline substances. It is also known that since it is reactive with oxidizing agents, acidic and alkaline substances and sensitive to light, it should be stored in tightly closed containers that are resistant to light.
- topical dosage forms such as creams comprising clobetasol and other ingredients tend to exhibit stability problems, including phase separation and formation of degradation products in shelf-life stability conditions especially at high temperature and moisture.
- commercially available reference product of clobetasol propionate 0.05% Cream, Dermovate® has the propension of undergoing formation of degradation products during the storage in the presence of heat and moisture. Consequently, there is a need to develop formulation and manufacturing process methods for the production of robust and stable product of clobetasol propionate containing topical formulations.
- the problem which the present invention sets out to solve here is therefore to devise a physically and chemically stable composition that allows clobetasol propionate to be combined in a composition, the composition according to the invention also being easy to use and having an acceptable cosmetic character for application to all areas of the body.
- the superiority of the present invention with the formulations described in the prior art and reference product is the enhanced stability of the topical formulation with optimizing the amount of used excipients while having same in vitro release which is shown by in vitro release testing for topical cream formulations.
- the present invention showed to our surprise that the finished product, being formulated with certain proportions of cetocearyl alcohol and glyceryl stearate, and especially the formula containing citric acid, surprisingly prevents degradation of the product, and as a result the finished product has superior chemical stability, consequently providing the product a surprisingly long durability.
- An object of the present invention is to provide stabilized pharmaceutical topical formulation of clobetasol or pharmaceutically acceptable salts thereof as active ingredient.
- An object of the present invention is to formulate a storage stable pharmaceutical topical composition of clobetasol or pharmaceutically acceptable salts thereof, said formulation comprises 5.0% to 12.0% (w/w) of cetostearyl alcohol based on the total composition and 5.0% to 14.0% (w/w) of glyceryl stearate based on the total composition, wherein the composition with comprising comprises citric acid as pH modifier.
- Topical drug delivery systems can be described as self-contained, discrete pharmaceutical semi-solid dosage forms designed to deliver an Active Pharmaceutical Ingredient (API) via the intact skin or body surface, for the purpose of generating a local or regional effect.
- Topical preparations for cutaneous application are usually comprised of one or more API dissolved or dispersed in a suitable semi-solid base which may be hydrophobic or hydrophilic. Topical dosage forms and their physical properties are summarized below;
- Creams and emulsions are the most diverse and widely used dosage forms for topical dermatological applications.
- Creams are “creamy white” viscous semisolid dosage forms that contain one or more drug substances dissolved or dispersed in a suitable base. They are two-phase systems typically containing hydrophilic ingredient in an aqueous phase and lipophilic ingredients in an oil phase. The two-phase system term traditionally has been applied to semisolids that possess a relatively soft, spreadable consistency formulated as either water-in-oil or oil-in-water emulsions. They are two- phase systems typically containing hydrophilic ingredient in an aqueous phase and lipophilic ingredients in an oil phase. In order for topical emulsions to function effectively they require certain functional excipients.
- All formulations contain excipients that form the vehicle that is necessary for delivering an API into and/or through the skin.
- the vehicle is comprised of ingredients used to adjust the pH of the formulation, promote the delivery and prolong the effect of an API on the skin surface or in the stratum corneum in addition to making the topical product cosmetically appealing.
- the selection of components of a topical formulation depends on a number of factors. The surface area to be treated, the nature of the lesion and the degradation profile of the active substance are critical. Often an API is available in a number of different formulations and/or delivery systems and maintains a basic activity, regardless of the type of system. However their ease of use, cost and efficacy for the desired purpose are affected by the formulation selected as ideal, in addition to the method of application.
- excipients for a specific API and production methods influence the stability of the product, magnitude of absorption and consequently the bioavailability and efficacy of the API.
- the excipients that comprise the vehicle modulate the effects of partitioning and diffusion of the API into and through the stratum corneum.
- excipients used in topical composition and production methods of the composition play a major role in the appearance, feel and successful application of an API. It is therefore critical to choose the most appropriate excipients with proper percentages and the most appropriate production method for a topical composition in order to achieve a desired therapeutic outcome.
- terapéuticaally effective amount refers to an amount, which achieves a desired effect, when administered to a living subject.
- the relative amount of the clobetasol propionate is 0.05% (w/w) based on the total composition.
- weight percentages refer to the weight of the component relative to weight of the composition.
- topical composition (synonymously, “topical formulation”) is used herein to refer to a pharmaceutical preparation intended for topical or local application to an afflicted region of a subject in need thereof, and includes such dosage forms as gel, cream, ointment, emulsion, suspension, solution, drops, lotion, spray or foam.
- topical formulation is in the form of a cream.
- stable refers to a composition that substantially maintains its physical and chemical properties when stored. Especially, appearance, identification, content uniformity, pH, viscosity, assay, related compounds, microbiological tests and in-vitro release testing results of the composition should not be extremely changed after production (To, initially) and during the storage conditons throughout the shelf life.
- Physical stability is understood according to the invention as applying to a composition that does not undergo any modification of macroscopic appearance (phase separation, change of colour or appearance, etc.) or microscopic appearance (recrystallization of active ingredients) after shelf life storage.
- No phase separation should be observed in either aqueous and/or non-aqueous components. More preferably, no phase separation should be observed in either aqueous and/or nonaqueous components for about 6 months at 40°C ⁇ 2°C, 75%RH ⁇ 5% and about 12 months at 25°C ⁇ 2°C/ 60%RH ⁇ 5%.
- Phase separation is a problem that can be encountered over time in topical forms when there is a tendency for phase decomposition.
- the manufacturing process results in a homogeneous emulsion
- the product if it is stored for any length of time before being used, it may start to separate into aqueous and non-aqueous phases and present a "curdled" (volume of clear serum topped by a distinct "creamy” phase) product to the consumer.
- this phenomenon may create an adverse impression in the minds of some consumers regarding the product's quality and acceptability.
- composition stability is understood according to the invention as applying to a composition in which the active principle content remains stable.
- a stable active principle content means according to the invention that the content varies very little relative to the initial content, i.e. that the variation in active principle content at time T must not be less than 90% of the initial content at TO and preferably not less than 95% of the initial content at TO.
- the pharmaceutical compositions described herein can, if desired, include one or more pharmaceutically acceptable excipients.
- excipient herein means any substance, not itself a therapeutic agent, which may be used as a carrier or vehicle for delivery of a therapeutic agent to a subject or combined with a therapeutic agent (e.g., to create a pharmaceutical composition) to improve its handling or storage properties or to permit or facilitate formation of a dose unit of the composition.
- Excipients include, by way of illustration and not limitation, binders, disintegrants, taste enhancers, solvents, thickening or gelling agents (and any neutralizing agents, if necessary), penetration enhancers, solubilizing agents, wetting agents, antioxidants, lubricants, emollients, emulsifying agents, surfactants, substances added to mask or counteract a disagreeable odor, fragrances or taste, and substances added to improve appearance or texture of the composition.
- Enhancers may interact with intercellular lipids to increase the diffusibility of an API into the horny layer of the skin. Furthermore, enhancers may increase the solubility of an API in a formulation vehicle and/or improve its partition coefficient.
- Propylene glycol, ethanol, dimethyl sulfoxide (DMSO) are examples of penetration enhancers.
- DMSO dimethyl sulfoxide
- Propylene glycol is also known as propane-1-2 diol and is a clear, viscous, hygroscopic liquid that is miscible with water and alcohol. It is widely used in pharmaceutical manufacturing as a solvent or vehicle in order to dissolve insoluble API or those that are unstable in water.
- an emulsifying agent The main purpose of an emulsifying agent is to form a condensed film around each of the droplets of the dispersed phase.
- a low concentration of emulsifier will have little/no effect on the stability of a cream.
- an increase in the concentration of the emulsifying agent will increase the stability of a topical formulation dramatically.
- the selection of a suitable emulsifier is usually the first step in the development of a cream.
- the emulsifier must be compatible with all other formulation excipients and the API to be included in the formulation. It should be non-toxic, stable and promote emulsification to maintain the stability of the topical formulation for the intended shelf-life of a product.
- the presence of an emulsifier may also increase the skin penetration of any API contained in that formulation.
- glyceryl stearate In the present invention, glyceryl stearate, Arlacel 165 and PEG 100 stearate were used as emulsifier.
- Glyceryl stearate also referred to as glyceryl monostearate, is essential for this invention.
- Topical cream formulation can be produced using a simple, flexible process.
- development of topical formulations is complex and therefore requires tightly controlled processing parameters.
- the top five critical process parameters and additional strategies for optimizing the manufacturing process for topical cream dosage forms are as follows; Temperature, heating and cooling rates, mixing methods and speeds, mixing times, flow rates.
- Creams for example, primarily comprise an aqueous phase and an oily phase. Phases are also important for the viscosity of the finished product. Adding ingredients in the correct phase contributes to overall stability. Also, the manufacturing process must be designed to protect active ingredient from physical and chemical degradation.
- Topical formulations contain several excipients and preservatives in addition to low concentrations of the API of interest, making the development of a stable topical formulation rather challenging.
- the choice of the excipients to be used to ensure that the API is stable and is released to the biological system under the best conditions is one of the most important factors to be assessed during formulation studies.
- the physicochemical properties of the API both in the solid state and in solution must be assessed at an early stage of formulation development.
- Other relevant physicochemical properties include information relating to pH-solubility and stability profiles, drug-excipient compatibility, melting point of excipients and degradation studies of the API.
- Clobetasol propionate the active ingredient of Clobetasol Propionate 0.05% Cream, is an effective corticosteroid and is indicated for the relief of inflammatory and pruritic symptoms of corticosteroid-sensitive dermatoses.
- Clobetasol 0.05% Cream contains propylene glycol and water as a moisturizer, chlorocresol as an antimicrobial preservative, glyceryl monostearate and Arlacel 165 as an emulsifying agent, beeswax and cetostearyl alcohol as a thickener, and citric acid and sodium citrate dihydrate as pH regulator, apart from the active substance clobetasol propionate. All the excipients in the formula are excipients used in pharmaceutical technology and are included in the European Pharmacopoeia and USP monographs and comply with the relevant specifications.
- the pharmaceutical composition according to the invention may also contain inert additives or combinations of these additives, such as wetting agents, flavour improvers, preservatives, stabilizers, humidity regulators, pH regulators, osmotic pressure modifiers, emulsifiers, penetrating agents, and synthetic polymers.
- inert additives or combinations of these additives such as wetting agents, flavour improvers, preservatives, stabilizers, humidity regulators, pH regulators, osmotic pressure modifiers, emulsifiers, penetrating agents, and synthetic polymers.
- the pharmaceutical composition of the present invention has the following composition:
- Citric acid monohydrate pH Adjuster Citric acid monohydrate pH Adjuster
- Test-1 was failed to form cream dosage form with having viscosity problems.
- Test-2 and Test-3 were failed with physical and chemical degradation (phase separation and yellowing problems in short term storage).
- Test-4, Test-5 and Test-6 products were subjected to accelerated and long term storage stability tests.
- Example 3 In Vitro Release Testing
- candidate compositions can be ranked based on in vitro release rates through artificial or post mortem skin membranes. This is routinely undertaken using the Franz Diffusion Cell methodology. The rate and extent to which the drug substance is released from the product matrix are particularly relevant to the prediction of relative efficacy of candidate formulations.
- IVRT In Vitro Release Testing
- SUPAC-SS The FDA Guidance on Scale up and Post Approval Changes for Semisolid (SUPAC-SS) describes suitable conditions for this testing.
- the apparatus used for IVRT is a Franz diffusion cell system. It consists of six individual cells. Each cell has a standard open cap ground glass surface with 15 mm diameter orifices, 35 mL volume capacity, and total diameter of 25 mm. About 300 mg of the semisolid preparation is placed uniformly on a synthetic membrane and kept occluded to prevent solvent evaporation and compositional changes.
- Each aliquot removed is then typically analyzed, for example, by high performance liquid chromatography (i.e., HPLC). After each aliquot was removed, the cell was refilled with a volume of fresh medium equal to the volume of the aliquot that was removed.
- HPLC high performance liquid chromatography
- Receptor medium (Potassium phosphate saline pH 7.4)
- test products comprising clobetasol propionate was tested in vitro and they were compared with a commercial reference product (Dermovate Cream 0.05% manufactured by GlaxoSmithKline).
- clobetasol propionate cream Specification for the clobetasol propionate cream is adequate to ensure the identity, strength, purity, and quality of the drug product during its expiration dating period.
- Typical stability parameters are the homogeneity of the formulation, the absence of coalescence of the emulsion droplets (no “coagulation”), a practically constant viscosity, semisolid structures, and no subsequent crystallization of the active ingredient out of the emulsion.
- the pH of the product is monitored throughout the stability process and should have similar results to the pH value originally present.
- Chlorocresol in the formulation of the present invention is an antimicrobial preservative and is important for topical products as they are used to prevent the growth of microorganisms and to protect pharmaceutical products from decomposition or fermentation, consequently it is monitored throughout the stability period.
- Test Products Test-4 & Test-5 & Test-6) and Reference Product (Dermovate 0.05% Cream) were measured. Results were found between pH 5 - 7.
- inventive products of topical pharmaceutical composition comprising; a therapeutically effective amount of clobetasol or its pharmaceutically acceptable salt thereof, 5.0% to 12.0% (w/w) of cetostearyl alcohol based on the total composition, 5.0% to 14.0% (w/w) of glyceryl stearate based on the total composition, wherein the composition comprises citric acid as pH modifier, is chemically and physically stable. It also has a very good patient acceptability and tolerance, due to its cream formula, as described in the examples of the present invention.
- the composition according to the invention is therefore found to be particularly suitable for the treatment of dermatological complaints and more particularly for the treatment of psoriasis.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a storage stable clobetasol topical formulation comprising cetostearyl alcohol and glyceryl stearate in a specific weight percent based on the total composition and comprising citric acid as a pH modifier. The amount of citric acid in the formulation is at least 0.05% (w/w) and the product has a pH of 5 to 7 throughout the stability condition.
Description
STORAGE STABLE TOPICAL COMPOSITION COMPRISING CLOBETASOL
Technical field:
A new topical formulation with high stability is provided, the composition comprising clobetasol or pharmaceutically acceptable salts thereof. It is associated with disorders including psoriasis, eczema, and other forms of dermatitis with exhibiting physical and chemical stability at long term shelf life stability condition.
Prior Art:
Clobetasol propionate is a synthetic, fluorinated corticosteroid with chemical name 21- chloro-9-fluoro-1 ip-hydroxy-16p-methyl-3,20- dioxopregna-1 ,4-dien- 17-yl propanoate, and it has the following structural formula (Formula I) with having only one polymorphic form and chiral with 8 stereogenic centers:
Formula I
Clobetasol propionate has an empirical formula of C25H32CIFO5 and a molecular weight of 467 g/mol. It is a white to cream-colored crystalline powder practically insoluble in water. It has been shown to be physically and chemically stable at room temperature (25°C/60% RH). Clobetasol is a very potent topical corticosteroid indicated for adults, elderly and children over 1 year for the short term treatment only of more resistant inflammatory and pruritic manifestations of steroid responsive dermatoses unresponsive to less potent corticosteroids. These include the following psoriasis (excluding widespread plaque psoriasis), recalcitrant dermatoses, lichen planus, discoid lupus erythematosus and other skin conditions which do not respond satisfactorily to less potent steroids.
Topical clobetasol propionate is a corticosteroid that is currently one of the most used treatments for psoriasis and its safety and efficacy is well defined in the medical literature.
The cream dosage form of clobetasol propionate is commercially marketed under the trade name of Dermovate® (GlaxoSmithKline, UK) comprising clobetasol propionate 0.05% (w/w).
Dermatitis is a superficial inflammation of the skin, characterized by vesicle formation, erythema, edema, oozing, scaling or crusting lesions, and intense itching. Different types of dermatitis can be distinguished: contact dermatitis, caused by irritants in contact with the skin or by non-irritating substances, to which the subject is allergic; atopic dermatitis, characterized by strong itching and a chronic course; and seborrheic dermatitis, a scaling disease mainly affecting the face and scalp.
One particular form of dermatitis is psoriasis, a chronic, inflammatory, hyper proliferative recurring disease, which affects the skin and joints. In its most typical form, it causes thick, red, scaly patches, called psoriatic plaques, to appear on the skin. Skin rapidly accumulates at these sites and takes on a silvery-white appearance. Plaques most often occur on the skin of the elbows, knees, scalp, lower back, face, palms, and soles of the feet but can affect any skin site.
Another form of dermatitis or inflammation of the epidermis is eczema, persistent skin conditions including dryness and recurring skin rashes. Other skin and mucous membrane conditions include disorders in the mouth, in the vagina, anus, ear and the eyes. Lichen planus is a chronic mucocutaneous disease that affects the skin and the oral mucosa, and presents itself in the form of papules, lesions or rashes.
Psoriasis is a lifelong disorder with onset at any time throughout life, affecting men and women equally and afflicts almost all races in varying frequency rates. Psoriasis usually appears first between the ages of 15 and 30 years and may occur anywhere on the body. Psoriasis causes significant psychological and social distress, and significantly impacts quality of life. Unsatisfactory treatment of the disorder has a considerable adverse impact on patient’s quality of life with patients complaining about the messiness of the topical agents used.
Clobetasol propionate is commercially available in compositions for topical application in form of lotion, spray, cream or shampoo. Moreover, various topical pharmaceutical compositions comprising clobetasol propionate has been proposed in the prior art, claiming the use of particular carriers or excipients.
WO 2006115987 in the name of Dow Pharmaceutical Sciences provides a method for treating psoriasis by spraying a pharmaceutical composition containing an effective
amount of clobetasol propionate onto the skin with psoriasis, using a daily treatment for at least 4 weeks. The preferred composition is a spray formulation of clobetasol propionate 0.05%, containing alcohol, isopropyl myristate, an anionic surfactant such as sodium lauryl sulfate, and optionally an antimicrobial compound such as an antifungal compound like undecylenic acid.
WO 2007104895 and WO 2007104897 in the name of Galderma disclosed oil-in-water (o/w) anti-inflammatory emulsions, containing: a) a therapeutically effective amount of at least one steroidal anti-inflammatory agent, notably clobetasol propionate; b) a propenetrating system which includes at least one pro-penetrating glycol and at least one other pro-penetrating agent; a polymeric or non-polymeric emulsifier or one gelling agent. In both cases preferred pro-penetration system are: propylene glycol and isosorbide dimethyl, propylene glycol and ethanol; propylene glycol, monoethylether of diethylene glycol and propylene glycol laurate; propylene glycol and methyl pyrrolidone; propylene glycol, isosorbide dimethyl and ethanol; propylene glycol, methyl pyrrolidone and oleic alcohol.
Other documents of the prior art propose the use of clobetasol in combination with at least a further active ingredient, such as calcitriol (Vitamin D) (see for example W02008110815, EP 1854.466, EP 1875916, US Patent No.2005281850, US Patent No. 2006009426 and FR 2848454): a progesterone derivative (EP 1473300); a prostaglandin (W003092617); or tazarotene (CA2282682).
Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation. Topical corticosteroids can be absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the product formulation and the integrity of the epidermal barrier. Occlusion, inflammation, and/or other disease processes in the skin may also increase percutaneous absorption. Once absorbed through the skin, topical corticosteroids are metabolized, primarily in the liver, and are then excreted by the kidneys. Some corticosteroids and their metabolites are also excreted in the bile.
Dermatological corticosteroids and in particular clobetasol propionate have been provided in a variety of topical formulations such as creams, lotions, gels and the like in attempts to increase the delivery efficiency. However, while enabling direct, localized application of the active agent to the skin surface, these formulations have not provided a complete solution to the problems connected with the stability problems due to degradation of topical compositions.
In previous literature studies, clobetasol propionate was found to be incompatible with alkaline substances. It is also known that since it is reactive with oxidizing agents, acidic and alkaline substances and sensitive to light, it should be stored in tightly closed containers that are resistant to light.
It has been recognized that topical dosage forms such as creams comprising clobetasol and other ingredients tend to exhibit stability problems, including phase separation and formation of degradation products in shelf-life stability conditions especially at high temperature and moisture. In addition, commercially available reference product of clobetasol propionate 0.05% Cream, Dermovate®, has the propension of undergoing formation of degradation products during the storage in the presence of heat and moisture. Consequently, there is a need to develop formulation and manufacturing process methods for the production of robust and stable product of clobetasol propionate containing topical formulations.
The problem which the present invention sets out to solve here is therefore to devise a physically and chemically stable composition that allows clobetasol propionate to be combined in a composition, the composition according to the invention also being easy to use and having an acceptable cosmetic character for application to all areas of the body.
The superiority of the present invention with the formulations described in the prior art and reference product is the enhanced stability of the topical formulation with optimizing the amount of used excipients while having same in vitro release which is shown by in vitro release testing for topical cream formulations.
The present invention showed to our surprise that the finished product, being formulated with certain proportions of cetocearyl alcohol and glyceryl stearate, and especially the formula containing citric acid, surprisingly prevents degradation of the product, and as a result the finished product has superior chemical stability, consequently providing the product a surprisingly long durability.
Description of the Invention:
An object of the present invention is to provide stabilized pharmaceutical topical formulation of clobetasol or pharmaceutically acceptable salts thereof as active ingredient.
An object of the present invention is to formulate a storage stable pharmaceutical topical composition of clobetasol or pharmaceutically acceptable salts thereof, said formulation comprises 5.0% to 12.0% (w/w) of cetostearyl alcohol based on the total composition and 5.0% to 14.0% (w/w) of glyceryl stearate based on the total composition, wherein the composition with comprising comprises citric acid as pH modifier.
Topical drug delivery systems can be described as self-contained, discrete pharmaceutical semi-solid dosage forms designed to deliver an Active Pharmaceutical Ingredient (API) via the intact skin or body surface, for the purpose of generating a local or regional effect. Topical preparations for cutaneous application are usually comprised of one or more API dissolved or dispersed in a suitable semi-solid base which may be hydrophobic or hydrophilic. Topical dosage forms and their physical properties are summarized below;
Creams and emulsions are the most diverse and widely used dosage forms for topical dermatological applications. Creams are “creamy white” viscous semisolid dosage forms that contain one or more drug substances dissolved or dispersed in a suitable base. They are two-phase systems typically containing hydrophilic ingredient in an aqueous phase and lipophilic ingredients in an oil phase. The two-phase system term traditionally has been applied to semisolids that possess a relatively soft, spreadable consistency formulated as either water-in-oil or oil-in-water emulsions. They are two- phase systems typically containing hydrophilic ingredient in an aqueous phase and lipophilic ingredients in an oil phase. In order for topical emulsions to function effectively they require certain functional excipients. Their consistency and rheological
behaviour depend on the properties and the nature of the materials used to produce the internal or dispersed phase. Therefore, selection of excipients and determination of the amount to be used are critical especially in two phase topical formulation in order to prevent phase separation. Consequently, this composition has been developed in order to eliminate the stability problems, especially phase separation and degradation, with respect to commercially available products.
All formulations contain excipients that form the vehicle that is necessary for delivering an API into and/or through the skin. In general, the vehicle is comprised of ingredients used to adjust the pH of the formulation, promote the delivery and prolong the effect of an API on the skin surface or in the stratum corneum in addition to making the topical product cosmetically appealing. The selection of components of a topical formulation depends on a number of factors. The surface area to be treated, the nature of the lesion and the degradation profile of the active substance are critical. Often an API is available in a number of different formulations and/or delivery systems and maintains a basic activity, regardless of the type of system. However their ease of use, cost and efficacy for the desired purpose are affected by the formulation selected as ideal, in addition to the method of application.
When developing formulations for topical delivery, the choices of excipients for a specific API and production methods influence the stability of the product, magnitude of absorption and consequently the bioavailability and efficacy of the API. The excipients that comprise the vehicle modulate the effects of partitioning and diffusion of the API into and through the stratum corneum. Furthermore, excipients used in topical composition and production methods of the composition play a major role in the appearance, feel and successful application of an API. It is therefore critical to choose the most appropriate excipients with proper percentages and the most appropriate production method for a topical composition in order to achieve a desired therapeutic outcome.
The term “therapeutically effective amount” refers to an amount, which achieves a desired effect, when administered to a living subject. In the present invention, the relative amount of the clobetasol propionate is 0.05% (w/w) based on the total composition.
In this invention, weight percentages (w/w) refer to the weight of the component relative to weight of the composition.
The term "topical composition" (synonymously, "topical formulation") is used herein to refer to a pharmaceutical preparation intended for topical or local application to an afflicted region of a subject in need thereof, and includes such dosage forms as gel, cream, ointment, emulsion, suspension, solution, drops, lotion, spray or foam. In the present invention, the topical formulation is in the form of a cream.
As used herein, “stable” refers to a composition that substantially maintains its physical and chemical properties when stored. Especially, appearance, identification, content uniformity, pH, viscosity, assay, related compounds, microbiological tests and in-vitro release testing results of the composition should not be extremely changed after production (To, initially) and during the storage conditons throughout the shelf life.
"Physical stability" is understood according to the invention as applying to a composition that does not undergo any modification of macroscopic appearance (phase separation, change of colour or appearance, etc.) or microscopic appearance (recrystallization of active ingredients) after shelf life storage. No phase separation should be observed in either aqueous and/or non-aqueous components. More preferably, no phase separation should be observed in either aqueous and/or nonaqueous components for about 6 months at 40°C±2°C, 75%RH ± 5% and about 12 months at 25°C±2°C/ 60%RH ± 5%.
Phase separation is a problem that can be encountered over time in topical forms when there is a tendency for phase decomposition. Thus, whilst the manufacturing process results in a homogeneous emulsion, if the product is stored for any length of time before being used, it may start to separate into aqueous and non-aqueous phases and present a "curdled" (volume of clear serum topped by a distinct "creamy" phase) product to the consumer. In general, this phenomenon may create an adverse impression in the minds of some consumers regarding the product's quality and acceptability.
"Chemical stability" is understood according to the invention as applying to a composition in which the active principle content remains stable. A stable active principle content means according to the invention that the content varies very little relative to the initial content, i.e. that the variation in active principle content at time T must not be less than 90% of the initial content at TO and preferably not less than 95% of the initial content at TO.
The pharmaceutical compositions described herein can, if desired, include one or more pharmaceutically acceptable excipients. The term "excipient" herein means any substance, not itself a therapeutic agent, which may be used as a carrier or vehicle for delivery of a therapeutic agent to a subject or combined with a therapeutic agent (e.g., to create a pharmaceutical composition) to improve its handling or storage properties or to permit or facilitate formation of a dose unit of the composition. Excipients include, by way of illustration and not limitation, binders, disintegrants, taste enhancers, solvents, thickening or gelling agents (and any neutralizing agents, if necessary), penetration enhancers, solubilizing agents, wetting agents, antioxidants, lubricants, emollients, emulsifying agents, surfactants, substances added to mask or counteract a disagreeable odor, fragrances or taste, and substances added to improve appearance or texture of the composition.
Enhancers may interact with intercellular lipids to increase the diffusibility of an API into the horny layer of the skin. Furthermore, enhancers may increase the solubility of an API in a formulation vehicle and/or improve its partition coefficient. Propylene glycol, ethanol, dimethyl sulfoxide (DMSO) are examples of penetration enhancers. Propylene glycol is also known as propane-1-2 diol and is a clear, viscous, hygroscopic liquid that is miscible with water and alcohol. It is widely used in pharmaceutical manufacturing as a solvent or vehicle in order to dissolve insoluble API or those that are unstable in water.
The main purpose of an emulsifying agent is to form a condensed film around each of the droplets of the dispersed phase. A low concentration of emulsifier will have little/no effect on the stability of a cream. However an increase in the concentration of the emulsifying agent will increase the stability of a topical formulation dramatically. The selection of a suitable emulsifier is usually the first step in the development of a cream. The emulsifier must be compatible with all other formulation excipients and the API to be included in the formulation. It should be non-toxic, stable and promote emulsification to maintain the stability of the topical formulation for the intended shelf-life of a product. The presence of an emulsifier may also increase the skin penetration of any API contained in that formulation. In the present invention, glyceryl stearate, Arlacel 165 and PEG 100 stearate were used as emulsifier. Glyceryl stearate, also referred to as glyceryl monostearate, is essential for this invention.
An ideal topical cream formulation can be produced using a simple, flexible process. However, the development of topical formulations is complex and therefore requires tightly controlled processing parameters. The top five critical process parameters and
additional strategies for optimizing the manufacturing process for topical cream dosage forms are as follows; Temperature, heating and cooling rates, mixing methods and speeds, mixing times, flow rates.
Other than critical process parameters, adding ingredients in the optimal phase and order are also critical for the production of the topical composition. Creams, for example, primarily comprise an aqueous phase and an oily phase. Phases are also important for the viscosity of the finished product. Adding ingredients in the correct phase contributes to overall stability. Also, the manufacturing process must be designed to protect active ingredient from physical and chemical degradation.
The following examples are for the purpose of illustration of the invention only and are not intended in any way to limit the scope of the present invention.
Example 1.
Topical formulations contain several excipients and preservatives in addition to low concentrations of the API of interest, making the development of a stable topical formulation rather challenging. The choice of the excipients to be used to ensure that the API is stable and is released to the biological system under the best conditions is one of the most important factors to be assessed during formulation studies.
The physicochemical properties of the API both in the solid state and in solution must be assessed at an early stage of formulation development. Other relevant physicochemical properties include information relating to pH-solubility and stability profiles, drug-excipient compatibility, melting point of excipients and degradation studies of the API.
Clobetasol propionate, the active ingredient of Clobetasol Propionate 0.05% Cream, is an effective corticosteroid and is indicated for the relief of inflammatory and pruritic symptoms of corticosteroid-sensitive dermatoses.
At the beginning of product development studies; PDR and literature, drug master file (DMF) of the active substance were used for the selection of excipients. In addition, the properties of the finished product were determined by taking into account the content, pH and viscosity of the formulation of the reference product. Clobetasol 0.05% Cream contains propylene glycol and water as a moisturizer, chlorocresol as an antimicrobial preservative, glyceryl monostearate and Arlacel 165 as an emulsifying agent, beeswax and cetostearyl alcohol as a thickener, and citric acid and sodium citrate dihydrate as pH regulator, apart from the active substance clobetasol propionate. All the excipients
in the formula are excipients used in pharmaceutical technology and are included in the European Pharmacopoeia and USP monographs and comply with the relevant specifications.
The pharmaceutical composition according to the invention may also contain inert additives or combinations of these additives, such as wetting agents, flavour improvers, preservatives, stabilizers, humidity regulators, pH regulators, osmotic pressure modifiers, emulsifiers, penetrating agents, and synthetic polymers.
In a preferred embodiment of the invention, the pharmaceutical composition of the present invention has the following composition:
Table 1 : Composition of the product - Clobetasol Propionate %0,05 Cream
Raw Material Function
Clobetasol propionate Active substance
Propylene glycol Moisturizer
Sodium citrate dihydrate pH Adjuster
Citric acid monohydrate pH Adjuster
Cetostearyl alcohol Viscosity increasing agent
Arlacel 165 Emulsifier
PEG 100 Stearate Emulsifier
Chlorocresol Antimicrobial preservative
Glyceryl monostearate Emulsifier
Beeswax Viscosity increasing agent
Water Diluent
Based on the dissolution of clobetasol propionate active ingredient in propylene glycol, the active ingredient was dissolved in propylene glycol and mixed with sodium citrate dehydrate, citric acid and water; this mixture formed the aqueous phase. Cetostearyl alcohol, glyceryl monostearate, Arlacel 165 and beeswax were mixed to form oily phase. The antimicrobial preservative, chlorocresol, was mixed with oily phase. Aqueous phase and oily phase were mixed to form the cream composition. The final product has a pH between 5 to 7 initially. The final product is homogenized and packed.
Example 2.
Amount % (w/w)
Test-1 Test-2 Test-3 Test-4 Test-5 Test-6
Clobetasol propionate 0.05 0.05 0.05 0.05 0.05 0.05
Propylene glycol 47.50 47.50 47.50 47.50 47.50 47.50
Sodium citrate dihydrate 0.05 0.05 0.05 0.05 0.05 0.05
Citric acid monohydrate . . . . o.O5 0.05
Cetostearyl alcohol 8.40 8.4 8.40 8.40 8.40 8.40
Arlacel 165 - - 11.00 8.75 6.00 2.50
PEG 100 Stearate 1.00 1.00
Glyseryl monostearate 5.00 12.50 - 11.00 5.80 10.00
Chlorocresol 0.10 0.10 0.10 0.10 0.10 0.10
Beeswax q.s. q.s. q.s. q.s. q.s. q.s.
Pure water q.s. q.s. q.s. q.s. q.s. q.s.
Test-1 was failed to form cream dosage form with having viscosity problems. Test-2 and Test-3 were failed with physical and chemical degradation (phase separation and yellowing problems in short term storage).
Test-4, Test-5 and Test-6 products were subjected to accelerated and long term storage stability tests. Example 3. In Vitro Release Testing
For a topical medicament to be effective, it must be readily released from the vehicle matrix and interact intimately with the skin to be treated. On this basis candidate compositions can be ranked based on in vitro release rates through artificial or post mortem skin membranes. This is routinely undertaken using the Franz Diffusion Cell methodology. The rate and extent to which the drug substance is released from the product matrix are particularly relevant to the prediction of relative efficacy of candidate formulations.
In Vitro Release Testing (IVRT) is a useful test to assess product "sameness" under certain scale and post approval changes for semisolid products. The FDA Guidance on
Scale up and Post Approval Changes for Semisolid (SUPAC-SS) describes suitable conditions for this testing. The apparatus used for IVRT is a Franz diffusion cell system. It consists of six individual cells. Each cell has a standard open cap ground glass surface with 15 mm diameter orifices, 35 mL volume capacity, and total diameter of 25 mm. About 300 mg of the semisolid preparation is placed uniformly on a synthetic membrane and kept occluded to prevent solvent evaporation and compositional changes. Multiple sampling times (at least 5 times) over an appropriate time period are suggested in order to generate an adequate release profile and to determine the drug release rate. Each aliquot removed is then typically analyzed, for example, by high performance liquid chromatography (i.e., HPLC). After each aliquot was removed, the cell was refilled with a volume of fresh medium equal to the volume of the aliquot that was removed.
The conditions used for IVRT for the example compositions of the invention are as follows:
Saline solution
Receptor medium (Potassium phosphate saline pH 7.4)
Speed 600 rpm
Membrane 0.45pm Nitrocellulose filter
Dosage 300 mg ± 30 mg
Temperature 32°C ± 0.5°C
Comparative in vitro release tests were conducted based on the above conditions. The test products (Test 4-6) comprising clobetasol propionate was tested in vitro and they were compared with a commercial reference product (Dermovate Cream 0.05% manufactured by GlaxoSmithKline).
As a result of in vitro release tests made, it was found that the reference product and Test products (Test 4-6) have similar release profiles according to the graphs obtained from the amounts of clobetasol propionate passing per unit cm2.
Example 4. Stability Studies
Specification for the clobetasol propionate cream is adequate to ensure the identity, strength, purity, and quality of the drug product during its expiration dating period.
In order to examine the physical and chemical stability of the products, stability test was assessed under accelerated condition (40°C±2°C, 75% Relative humidity,
RH±5%) and ambient temperature condition (25°C±2°C/ 60±5% Relative Humidity, RH±5%) for Test products (Test-4 to Test-6) and commercially available reference product (Dermovate 0.05% Cream - GlaxoSmithKline, 15C792).
Typical stability parameters are the homogeneity of the formulation, the absence of coalescence of the emulsion droplets (no “coagulation”), a practically constant viscosity, semisolid structures, and no subsequent crystallization of the active ingredient out of the emulsion. The pH of the product is monitored throughout the stability process and should have similar results to the pH value originally present.
Chlorocresol in the formulation of the present invention is an antimicrobial preservative and is important for topical products as they are used to prevent the growth of microorganisms and to protect pharmaceutical products from decomposition or fermentation, consequently it is monitored throughout the stability period.
The stability test results of assay and degradation are summarized in the Table 2 below.
Table 2. Stability results of Test Products (Test-4 & Test-5 & Test-6) and Reference Product (Dermovate 0.05% Cream)
* The pH of Test Products (Test-4 & Test-5 & Test-6) and Reference Product (Dermovate 0.05% Cream) were measured. Results were found between pH 5 - 7.
At room temperature, macroscopic observation makes it possible to guarantee the physical integrity of the products and microscopic observation makes it possible to verify that there is no recrystallization of the solubilized active ingredient.
The microbiological examinations were within limits at all examinations. No Escherichia coli were found initially or after storage.
The inventive products of topical pharmaceutical composition comprising; a therapeutically effective amount of clobetasol or its pharmaceutically acceptable salt thereof, 5.0% to 12.0% (w/w) of cetostearyl alcohol based on the total composition, 5.0% to 14.0% (w/w) of glyceryl stearate based on the total composition, wherein the composition comprises citric acid as pH modifier, is chemically and physically stable. It also has a very good patient acceptability and tolerance, due to its cream formula, as described in the examples of the present invention. The composition according to the invention is therefore found to be particularly suitable for the treatment of dermatological complaints and more particularly for the treatment of psoriasis.
Claims
1. A topical pharmaceutical composition having improved storage stability comprising;
(I) a therapeutically effective amount of clobetasol or its pharmaceutically acceptable salt thereof,
(II) 5.0% to 12.0% (w/w) of cetostearyl alcohol based on the total composition,
(III) 5.0% to 14.0% (w/w) of glyceryl stearate based on the total composition, wherein the composition comprises citric acid as pH modifier.
2. The pharmaceutical composition according to claim 1 , wherein the amount of citric acid is at least 0.05% (w/w) based on the total composition.
3. The pharmaceutical composition according to claim 1, wherein the amount of cetostearyl alcohol is 8.0% to 10.0% (w/w) based on the total composition.
4. The pharmaceutical composition according to claim 1 , wherein the amount of glyceryl stearate is 5.0% to 12.0% (w/w) based on the total composition.
5. The pharmaceutical composition according to claim 1 , wherein the composition comprises chlorocresol as antimicrobial preservative.
6. The pharmaceutical composition according to claim 1 , wherein the composition additionally comprises propylene glycol, sodium citrate, Arlacel 165, beeswax and water.
7. The pharmaceutical composition according to claim 1, wherein the composition has a pH of about 5 to about 7 initially and during the stability period.
8. The pharmaceutical composition according to claim 1 , wherein the composition is a cream dosage form.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/TR2022/050686 WO2024005726A1 (en) | 2022-06-30 | 2022-06-30 | Storage stable topical composition comprising clobetasol |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/TR2022/050686 WO2024005726A1 (en) | 2022-06-30 | 2022-06-30 | Storage stable topical composition comprising clobetasol |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024005726A1 true WO2024005726A1 (en) | 2024-01-04 |
Family
ID=89380988
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/TR2022/050686 WO2024005726A1 (en) | 2022-06-30 | 2022-06-30 | Storage stable topical composition comprising clobetasol |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024005726A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010094806A2 (en) * | 2009-02-23 | 2010-08-26 | Abigo Medical Ab | A topical formulation of low level clobetasol propionate for treating disorders of the skin and mucous membranes |
US20160184431A1 (en) * | 2014-03-11 | 2016-06-30 | Promius Pharma Llc | Topical compositions comprising a corticosteroid |
WO2018233878A1 (en) * | 2017-06-23 | 2018-12-27 | Laboratorios Salvat, S.A. | An oil-in-water nanoemulsion composition of clobetasol |
-
2022
- 2022-06-30 WO PCT/TR2022/050686 patent/WO2024005726A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010094806A2 (en) * | 2009-02-23 | 2010-08-26 | Abigo Medical Ab | A topical formulation of low level clobetasol propionate for treating disorders of the skin and mucous membranes |
US20160184431A1 (en) * | 2014-03-11 | 2016-06-30 | Promius Pharma Llc | Topical compositions comprising a corticosteroid |
WO2018233878A1 (en) * | 2017-06-23 | 2018-12-27 | Laboratorios Salvat, S.A. | An oil-in-water nanoemulsion composition of clobetasol |
Non-Patent Citations (1)
Title |
---|
FAUZEE AYESHAH FATEEMAH BEEBEE, WALKER RODERICK BRYAN: "The impact of formulation variables on the optimization of pilot scale clobetasol 17-propionate creams", COGENT ENGINEERING, vol. 7, no. 1, 1 January 2020 (2020-01-01), pages 1804713, XP093125782, ISSN: 2331-1916, DOI: 10.1080/23311916.2020.1804713 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6187763B1 (en) | Activated vitamin D3 emulsion-type lotions | |
JP7324210B2 (en) | Topical preparations containing tofacitinib | |
AU2019281888B2 (en) | Method and formulation for improving roflumilast skin penetration lag time | |
WO2012011566A1 (en) | Tacrolimus-containing oil-in-water type creamy composition | |
JP2002530271A (en) | Pharmaceutical composition comprising amphoteric surfactant alkoxylated cetyl alcohol and polar drug | |
US20220273627A1 (en) | Topical composition comprising tacrolimus | |
US20240100045A1 (en) | Emulsion composition and uses thereof in the prevention and/or treatment of skin damage caused by radiation | |
AU2021268977B2 (en) | Treatment of skin conditions using high Krafft temperature anionic surfactants | |
WO2024005726A1 (en) | Storage stable topical composition comprising clobetasol | |
JP2023536102A (en) | Topical Formulation Containing JAK Inhibitor and Laureth-4 | |
JP6084579B2 (en) | Oil-in-water cream composition containing tacrolimus | |
US9987239B1 (en) | Pharmaceutical retinoid preparation for topical use | |
JP2022549876A (en) | pharmaceutical formulation | |
WO2019082873A1 (en) | Coating-forming topical agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22949594 Country of ref document: EP Kind code of ref document: A1 |